Form 4: Adaptive Biotechnologies CFO Kyle Piskel Reports Stock Transactions

Chief Financial Officer of Adaptive Biotechnologies, Kyle Piskel, reports acquisition and disposition of company stock to cover tax obligations related to vesting RSUs.

Summary

• On March 4, 2025, Kyle Piskel, CFO of Adaptive Biotechnologies, acquired 125,000 shares of common stock.
• On March 5, 2025, Piskel sold 3,103 shares at $6.97, 253 shares at $6.98, and 6,964 shares at $6.99.
• These sales were to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following these transactions, Piskel directly owns 269,010 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a key executive, providing transparency.

Key Dates